The Non-Cystic Fibrosis Bronchiectasis Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Non-Cystic Fibrosis Bronchiectasis Market:
https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report
According to The Business Research Company’s Non-Cystic Fibrosis Bronchiectasis Global Market Report 2024, The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advances in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, growing research and development, public health initiatives, the global aging population, and the development of targeted therapies. Major trends in the forecast period include digital health solutions, a focus on targeted therapies, the integration of AI and machine learning, a shift towards home-based care, patient-centric approaches, and the growth of mobile health (mHealth) solutions.
The rising prevalence of respiratory diseases is expected to propel the growth of the non-cystic fibrosis bronchiectasis market going forward. Respiratory diseases encompass a range of conditions affecting the lungs and respiratory system, impacting breathing and overall respiratory function. The rising prevalence of respiratory diseases is primarily driven by increasing environmental pollution, including both outdoor pollutants and indoor irritants such as tobacco smoke. The increasing prevalence of respiratory infections presents opportunities for advancing understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health efforts. For instance, in June 2023, according to a report published by the Office for Health Improvement and Disparities, a UK-based governmental body, a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were received from week 37 to week 46 during the 2022-2023 season in England, with 851 notifications received in week 46 alone. This is significantly higher compared to an average of 1,294 notifications (ranging from 258 to 2,008) for the same period (weeks 37 to 46) over the previous five years. Therefore, the rising prevalence of respiratory diseases will drive the growth of the non-cystic fibrosis bronchiectasis market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp
The non-cystic fibrosis bronchiectasis market covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types
2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments
3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses
Major companies operating in the non-cystic fibrosis bronchiectasis market are focusing on personalized medicine approaches, such as nebulization solutions, to optimize drug delivery efficiency and patient compliance. Nebulization solutions offer advanced technology for precise and effective delivery of respiratory medications, enhancing patient compliance and treatment outcomes. For instance, in April 2022, Zambon S.P.A, an Italy-based multinational pharmaceutical company, received a US FDA designation for CMS I-neb therapy in patients with non-cystic fibrosis bronchiectasis (NCFB). CMS I-net is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa. NCFB is a chronic, progressive, and irreversible respiratory disease. The breakthrough designation validates the registrational path for CMS I-neb in NCFB and facilitates potentially expedited development and review.
The non-cystic fibrosis bronchiectasis market report table of contents includes:
1. Executive Summary
- Non-Cystic Fibrosis Bronchiectasis Market Characteristics
- Non-Cystic Fibrosis Bronchiectasis Market Trends And Strategies
- Non-Cystic Fibrosis Bronchiectasis Market – Macro Economic Scenario
- Global Non-Cystic Fibrosis Bronchiectasis Market Size and Growth
.
32. Global Non-Cystic Fibrosis Bronchiectasis Market Competitive Benchmarking
- Global Non-Cystic Fibrosis Bronchiectasis Market Competitive Dashboard
- Key Mergers And Acquisitions In The Non-Cystic Fibrosis Bronchiectasis Market
- Non-Cystic Fibrosis Bronchiectasis Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
